Royalty Pharma (RPRX)
(Delayed Data from NSDQ)
$36.49 USD
+0.17 (0.47%)
Updated Oct 2, 2025 04:00 PM ET
After-Market: $36.48 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RPRX 36.49 +0.17(0.47%)
Will RPRX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for RPRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RPRX
Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q2 Earnings
Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates
RPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Countdown to Royalty Pharma (RPRX) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
Other News for RPRX
Is RPRX signaling a buying opportunity? Crossed Above 20 Day Moving Average shows up after gaining 2.95%
Royalty Pharma: Strategic Positioning and Growth Potential Drive Buy Rating
Is RPRX lining up for a decline? Lower Bollinger Band Walk shows up after a relatively flat session
RPRX: Goldman Sachs Initiates Coverage with 'Buy' Rating | RPRX Stock News
Is RPRX poised for a breakout? NR7 shows up after climbing 0.6%